申请人:EMMENNAR PHARMA PRIVATE LIMITED
公开号:US20200331946A1
公开(公告)日:2020-10-22
The present invention relates to modified, improved processes for the preparation of sodium glucose co-transporter 2 (SGLT-2) inhibitors and intermediates thereof. More particularly, the present invention relates to improved processes for the preparation of gliflozin compounds such as empagliflozin and dapagliflozin, intermediates thereof. The product obtained from the processes of present invention may be amorphous or crystalline. Also, the products obtained from the present invention may be used for the preparation of medicaments for the prevention and/or treatment of diseases and conditions associated with SGLT-2 inhibition.
本发明涉及改进的,用于制备钠葡萄糖共转运体2(SGLT-2)抑制剂及其中间体的过程。更具体地,本发明涉及用于制备格列凡诺类化合物,如恩帕格列凡诺和达帕格列凡诺及其中间体的改进过程。本发明所得到的产物可以是非晶态或晶态。此外,本发明所得到的产物可用于制备药物,用于预防和/或治疗与SGLT-2抑制有关的疾病和症状。